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1LINICAL CHALLENGE
antle Cell Lymphoma in First Complete RemissionA 57-year-old man presented with axillary adenopathy. Biopsy of the axillary lymph node revealed
mantle cell lymphoma with a diffuse pattern. The malignant cells were CD10-, CD19, CD20 and
CD5. PET-CT scan demonstrated bilateral axillary adenopathy, splenomegaly and bulky retroperito-
neal adenopathy. FDG uptake was abnormal in all sites. Bone marrow biopsy revealed 20% involvement
with lymphoma. Cytogenetic analysis showed the t(11;14) karyotype and PCR confirmed the presence of
bcl-1. CBC was normal but LDH was elevated. The patient was staged as IVA. He received 6 cycles of
R-HyperCVAD and obtained a CR. Bone marrow biopsy shows no evidence of disease by morphology
and PCR. He has an HLA-matched sibling.
What’s your recommended therapy?
● Autologous HCT
● Allogeneic myeloablative HCT
● Reduced intensity allogeneic HCT
● Radioimmunoconjugate
● Rituximab maintenance
● Observation
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In a recent issue of the ASBMT eNEWS, readers
ere presented with the above Clinical Challenge
nd invited to use an online poll to recommend a
ourse of treatment. The reader recommendations
or therapy were:
35% Reduced intensity allogeneic HCT
27% Autologous HCT
15% Observation
10% Rituximab maintenance
9% Allogeneic myeloablative HCT
4% Radioimmunoconjugate
OMMENTARY
As seen in this case, the typical clinical course of
antle cell lymphoma is characterized by a high
esponse rate to initial therapy. However, progres-
ion within 2 years or less tends to be the rule. If
his patient was seen at our center, we would rec-
mmend consolidative therapy with reduced inten-
ity conditioning (RIC) HCT since a matched re-
ated donor has been identiﬁed. The existence of a
raft vs lymphoma effect is supported by reduced
elapse rates after allografts in comparison to con-
entional chemotherapy and autografts. Addition- r
118lly, RIC allografts have conferred responses in pa-
ients with relapsed/refractory disease including
fter a failed autograft [1,2]. If this patient did not
ave a MRD, my second choice would be autolo-
ous HCT as outcomes appear improved compared
o conventional treatment [3].
I would not recommend a myeloablative allo-
raft in light of this patient’s age and the associated
rohibitive nonrelapse mortality. The feasibility of
adioimmunoconjugates has been reported in this
etting [4] and we are awaiting the results of the
COG trial with which a single dose of Zevalin was
dministered after four cycles of R-CHOP as front-
ine therapy. Rituximab maintenance therapy after
nduction has been shown to prolong PFS but is
ssociated with myelosuppression [5]. And ﬁnally,
bservation can be offered since no existing thera-
ies have shown an unequivocal survival beneﬁt
ompared to observation in a large, randomized
rial. It should be acknowledged that this patient is
robably not cured but would have several options
nce he relapses.
As conﬁrmed by this poll, there is no uniform
greement and subsequent treatment decisions
hould be ultimately determined by the availability
f speciﬁc clinical trials as well as patient and phy-
ician consideration of the risk/beneﬁt ratio of cur-
ent options. The widespread distribution of votes
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Mantle Cell Lymphoma in First Complete Remission 1119ere reminds us that an unequivocally superior
herapy currently does not exist for mantle cell
ymphoma in ﬁrst remission.
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